SCHEMBL1624935

SCHEMBL1624935

Cc1ccc2[nH]c(-c3cc(N4CCC[C@@H](C(=O)NCCN5CCCC5)C4)ccc3Cl)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 1/20 0.42
TSHR P16473 3/20 0.42
ALDH1A1 P00352 2/20 0.42
RECQL P46063 2/20 0.42
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
HTT P42858 1/20 0.39
NOTUM Q6P988 1/20 0.39
ATR Q13535 1/20 0.39
DGAT2 Q96PD7 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1625167 1.00 GPBAR1 (0.43) GPBAR1SMN1; SMN2NPC1TSHRALDH1A1
SCHEMBL1625513 0.96 ALDH1A1 (0.45) GPBAR1SMN1; SMN2NPC1TSHRALDH1A1
SCHEMBL1284850 0.94 SMN1; SMN2 (0.51) GPBAR1SMN1; SMN2NPC1TSHRALDH1A1
SCHEMBL1623736 0.94 SMN1; SMN2 (0.51) GPBAR1SMN1; SMN2NPC1TSHRALDH1A1
SCHEMBL1625450 0.92 ALDH1A1 (0.46) TSHRALDH1A1RECQLLMNAMAPT
SCHEMBL1625656 0.91 HSD17B10 (0.41) GPBAR1SMN1; SMN2NPC1TSHRRAB9A
SCHEMBL1625651 0.91 HSD17B10 (0.41) GPBAR1SMN1; SMN2NPC1TSHRRAB9A
SCHEMBL1623594 0.90 CYP1A2 (0.43) GPBAR1SMN1; SMN2NPC1TSHRRAB9A
SCHEMBL1623983 0.90 ALDH1A1 (0.46) SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E
SCHEMBL1625627 0.89 GPBAR1 (0.42) GPBAR1TSHRKDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835648-B2 Hedgehog pathway antagonists and therapeutic applications thereof SIENA BIOTECH S.P.A. (IT) 2014-09-16 US disclosed
US-8835648-B2 Hedgehog pathway antagonists and therapeutic applications thereof SIENA BIOTECH S.P.A. (IT) 2014-09-16 US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SHH, GLI1, SMO GPBAR1 73/4885SMN1; SMN2 2687/4885NPC1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.